A Single-dose, Open-label, Phase I Study Comparing the Pharmacokinetics, Safety, and Pharmacodynamics of HRS-5965 in Subjects With Mild and Moderate Hepatic Impairment and Normal Hepatic Function
Latest Information Update: 02 Feb 2026
At a glance
- Drugs HRS-5965 (Primary)
- Indications Liver failure
- Focus Pharmacokinetics
- Sponsors Chengdu Suncadia Medicine
Most Recent Events
- 30 Jan 2026 Status changed from recruiting to completed.
- 11 Dec 2024 Status changed from not yet recruiting to recruiting.
- 08 Nov 2024 New trial record